Peloton Therapeutics, founded in Dallas, is a clinical-stage pharmaceutical company dedicated to developing innovative cancer treatment drugs. The company's core mission is to translate novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. Peloton Therapeutics focuses on targeting HIF-2α, a transcription factor previously considered intractable using small molecules. Their pioneering work in HIF-2α biology has positioned them as leaders in this niche field.

Notable affiliated individuals include scientists and researchers who have significantly contributed to the understanding of HIF-2α biology. Peloton Therapeutics has attracted investments from prominent venture capital firms and strategic partners in the biotech industry. Key achievements include the development of the first HIF-2α inhibitor to enter clinical development, marking a significant milestone in cancer treatment research. The company's innovative approach has the potential to make a substantial impact on the lives of patients with cancer and other serious conditions.